Background

Katia Verhamme is Associate Professor of Use and Analysis of observational data. Katia graduated as medical doctor from the University of Ghent and trained as General Practitioner.  Within the department of medical informatics, she is leading the pharmacoepidemiology group and is an expert on multi-database studies.  Since her PhD graduation as pharmaco-epidemiologist from the Erasmus University Medical Centre, Katia has successfully developed a research group conducting pharmaco-epidemiological research, using electronic patient records as compiled in various observational health care databases. She has a specific interest in the field of respiratory pharmaco-epidemiology and has successfully coordinated multiple Post-Authorisation Safety Studies requested by the EMA. She was/is principal investigator of international studies investigating the management of chronic respiratory conditions in real life. She is also guest professor Pharmaco-epidemiology at the Faculty of Pharmaceutical Sciences at the University of Ghent.

Articles

1.             Pane J, Verhamme KMC, Villegas D, Gamez L, Rebollo I, Sturkenboom M. Challenges Associated with the Safety Signal Detection Process for Medical Devices. Medical devices (Auckland, NZ). 2021;14:43-57.

2.             Hendriksen LC, Verhamme KMC, Van der Linden PD, Stricker BH, Visser LE. Women are started on a lower daily dose of metoprolol than men irrespective of dose recommendations: A potential source of confounding by contraindication in pharmacoepidemiology. Pharmacoepidemiology and drug safety. 2021.

3.             Edris A, de Roos EW, McGeachie MJ, Verhamme KMC, Brusselle GG, Tantisira KG, et al. Pharmacogenetics of inhaled corticosteroids and exacerbation risk in adults with asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2021.

4.             Benz E, Trajanoska K, Schoufour JD, Lahousse L, de Roos EW, Terzikhan N, et al. Sarcopenia in older people with chronic airway diseases: the Rotterdam study. ERJ open research. 2021;7(1).

5.             Vandael E, Latour K, Goossens H, Magerman K, Drapier N, Catry B, et al. Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017. Antimicrobial resistance and infection control. 2020;9(1):13.

6.             Pane J, Verhamme KMC, Shrum L, Rebollo I, Sturkenboom M. Blockchain technology applications to postmarket surveillance of medical devices. Expert review of medical devices. 2020;17(10):1123-32.

7.             Pane J, Verhamme KMC, Rebollo I, Sturkenboom M. Descriptive analysis of postmarket surveillance data for hip implants. Pharmacoepidemiology and drug safety. 2020;29(4):380-7.

8.             King C, McKenna A, Farzan N, Vijverberg SJ, van der Schee MP, Maitland-van der Zee AH, et al. Correction: Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritization. The pharmacogenomics journal. 2020;20(5):746.

9.             King C, McKenna A, Farzan N, Vijverberg SJ, van der Schee MP, Maitland-van der Zee AH, et al. Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. The pharmacogenomics journal. 2020;20(5):621-8.

10.           Hernandez-Pacheco N, Vijverberg SJ, Herrera-Luis E, Li J, Sio YY, Granell R, et al. Genome-wide association study of asthma exacerbations despite inhaled corticosteroids use. Eur Respir J. 2020.

11.           Hernandez-Pacheco N, Gorenjak M, Jurgec S, Corrales A, Jorgensen A, Karimi L, et al. Combined analysis of transcriptomic and genetic data for the identification of loci involved in glucocorticosteroid response in asthma. Allergy. 2020.

12.           Engelkes M, de Ridder MA, Svensson E, Berencsi K, Prieto-Alhambra D, Lapi F, et al. Multinational cohort study of mortality in patients with asthma and severe asthma. Respiratory medicine. 2020;165:105919.

13.           Engelkes M, Baan EJ, de Ridder MAJ, Svensson E, Prieto-Alhambra D, Lapi F, et al. Incidence, risk factors and re-exacerbation rate of severe asthma exacerbations in a multinational, multidatabase pediatric cohort study. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2020;31(5):496-505.

14.           Dijk FN, Vijverberg SJ, Hernandez-Pacheco N, Repnik K, Karimi L, Mitratza M, et al. IL1RL1 gene variations are associated with asthma exacerbations in children and adolescents using inhaled corticosteroids. Allergy. 2020;75(4):984-9.

15.           Ceschi A, Noseda R, Palin K, Verhamme K. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. Frontiers in pharmacology. 2020;11:557.

16.           Baan EJ, van den Akker ELT, Engelkes M, de Rijke YB, de Jongste JC, Sturkenboom M, et al. Hair cortisol and inhaled corticosteroid use in asthmatic children. Pediatric pulmonology. 2020;55(2):316-21.

17.           Baan EJ, de Smet VA, Hoeve CE, Pacurariu AC, Sturkenboom M, de Jongste JC, et al. Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports. Drug Saf. 2020;43(1):7-16.

18.           Arinze JT, Verhamme KMC, Luik AI, Stricker B, van Meurs JBJ, Brusselle GG. The interrelatedness of chronic cough and chronic pain. Eur Respir J. 2020.

19.           Arinze JT, de Roos EW, Karimi L, Verhamme KMC, Stricker BH, Brusselle GG. Prevalence and incidence of, and risk factors for chronic cough in the adult population: the Rotterdam Study. ERJ open research. 2020;6(2).

20.           Verhamme KMC, Lucet C, Van Meerhaeghe A, Brusselle GGO, Lambert ML. Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium. ERJ open research. 2019;5(4).

21.           Verhamme KMC, Bohnen AM. Are we facing an opioid crisis in Europe? The Lancet Public health. 2019;4(10):e483-e4.

22.           Pane J, Francisca RDC, Verhamme KMC, Orozco M, Viroux H, Rebollo I, et al. EU postmarket surveillance plans for medical devices. Pharmacoepidemiology and drug safety. 2019;28(9):1155-65.

23.           Mulder M, Baan E, Verbon A, Stricker B, Verhamme K. Trends of prescribing antimicrobial drugs for urinary tract infections in primary care in the Netherlands: a population-based cohort study. BMJ open. 2019;9(5):e027221.

24.           Karimi L, Vijverberg SJH, Farzan N, Ghanbari M, Verhamme KMC, Maitland-van der Zee AH. FCER2 T2206C variant associated with FENO levels in asthmatic children using inhaled corticosteroids: The PACMAN study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2019;49(11):1429-36.

25.           Karimi L, Lahousse L, Ghanbari M, Terzikhan N, Uitterlinden AG, van der Lei J, et al. ?(2)-Adrenergic Receptor (ADRB2) Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study. Journal of clinical medicine. 2019;8(11).

26.           Hernandez-Pacheco N, Farzan N, Francis B, Karimi L, Repnik K, Vijverberg SJ, et al. Genome-wide association study of inhaled corticosteroid response in admixed children with asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2019;49(6):789-98.

27.           Cheung K, Verhamme KMC, Herings R, Visser LE, Stricker BH. Methylphenidate Treatment Initiated During Childhood Is Continued in Adulthood in Half of the Study Population. Journal of child and adolescent psychopharmacology. 2019;29(6):426-32.

28.           Bulathsinhala L, Eleangovan N, Heaney LG, Menzies-Gow A, Gibson PG, Peters M, et al. Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. The journal of allergy and clinical immunology In practice. 2019;7(2):578-88.e2.

29.           Terzikhan N, Lahousse L, Verhamme KMC, Franco OH, Ikram AM, Stricker BH, et al. COPD is associated with an increased risk of peripheral artery disease and mortality. ERJ open research. 2018;4(4).

30.           Osokogu OU, Verhamme K, Sturkenboom M, Kaguelidou F. Pharmacoepidemiology in pediatrics: Needs, challenges and future directions for research. Therapie. 2018;73(2):151-6.

31.           Osokogu OU, Pacurariu A, Mosseveld M, Rijnbeek P, Weibel D, Verhamme K, et al. Impact of different assumptions on estimates of childhood diseases obtained from health care data: A retrospective cohort study. Pharmacoepidemiology and drug safety. 2018;27(6):612-20.

32.           Osokogu OU, Khan J, Nakato S, Weibel D, de Ridder M, Sturkenboom M, et al. Choice of time period to identify confounders for propensity score matching, affected the estimate: a retrospective cohort study of drug effectiveness in asthmatic children. Journal of clinical epidemiology. 2018;101:107-15.e3.

33.           Farzan N, Vijverberg SJ, Hernandez-Pacheco N, Bel EHD, Berce V, Bønnelykke K, et al. 17q21 variant increases the risk of exacerbations in asthmatic children despite inhaled corticosteroids use. Allergy. 2018;73(10):2083-8.

34.           Engelkes M, van Blijderveen JC, Overbeek JA, Kuiper J, Herings RCM, Sturkenboom M, et al. Brand and generic use of inhalation medication and frequency of switching in children and adults: A population-based cohort study. The Journal of asthma : official journal of the Association for the Care of Asthma. 2018;55(10):1086-94.

35.           de Roos EW, Lahousse L, Verhamme KMC, Braunstahl GJ, Ikram MA, In 't Veen J, et al. Asthma and its comorbidities in middle-aged and older adults; the Rotterdam Study. Respiratory medicine. 2018;139:6-12.

36.           Baan EJ, Janssens HM, Kerckaert T, Bindels PJE, de Jongste JC, Sturkenboom M, et al. Antibiotic use in children with asthma: cohort study in UK and Dutch primary care databases. BMJ open. 2018;8(11):e022979.

37.           Terzikhan N, Bos D, Lahousse L, Wolff L, Verhamme KMC, Leening MJG, et al. Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study. Eur Respir J. 2017;49(6).

38.           Pane J, Coloma PM, Verhamme KM, Sturkenboom MC, Rebollo I. Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines. Drug Saf. 2017;40(1):37-47.

39.           Ferrajolo C, Verhamme KM, Trifirò G, t Jong GW, Picelli G, Giaquinto C, et al. Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases. Drug Saf. 2017;40(4):305-15.

40.           Farzan N, Vijverberg SJ, Andiappan AK, Arianto L, Berce V, Blanca-López N, et al. Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. Pharmacogenomics. 2017;18(10):931-43.

41.           Duong JK, de Winter W, Choy S, Plock N, Naik H, Krauwinkel W, et al. The variability in beta-cell function in placebo-treated subjects with type 2 diabetes: application of the weight-HbA1c-insulin-glucose (WHIG) model. British journal of clinical pharmacology. 2017;83(3):487-97.

42.           Terzikhan N, Verhamme KM, Hofman A, Stricker BH, Brusselle GG, Lahousse L. Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. European journal of epidemiology. 2016;31(8):785-92.

43.           Lasky T, Artaman A, Czaja AS, Maruti SS, Osokogu OU, Verhamme KM, et al. Current needs in pediatric pharmacoepidemiology. Pharmacoepidemiology and drug safety. 2016;25(6):738-42.

44.           Lahousse L, Verhamme KM, Stricker BH, Brusselle GG. Cardiac effects of current treatments of chronic obstructive pulmonary disease. The Lancet Respiratory medicine. 2016;4(2):149-64.

45.           Huijgen NA, de Ridder MA, Verhamme KM, Dohle GR, Vanrolleghem AM, Sturkenboom MC, et al. Are proton-pump inhibitors harmful for the semen quality of men in couples who are planning pregnancy? Fertility and sterility. 2016;106(7):1666-72.e2.

46.           Engelkes M, Janssens HM, de Ridder MA, Sturkenboom MC, de Jongste JC, Verhamme KM. Real life data on incidence and risk factors of severe asthma exacerbations in children in primary care. Respiratory medicine. 2016;119:48-54.

47.           Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Prescription patterns, adherence and characteristics of non-adherence in children with asthma in primary care. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2016;27(2):201-8.

48.           de Bie S, Kaguelidou F, Verhamme KM, De Ridder M, Picelli G, Straus SM, et al. Using Prescription Patterns in Primary Care to Derive New Quality Indicators for Childhood Community Antibiotic Prescribing. The Pediatric infectious disease journal. 2016;35(12):1317-23.

49.           Blok CG, de Ridder MA, Verhamme KM, Moorman PW. Hypertension in older patients, a retrospective cohort study. BMC geriatrics. 2016;16:142.

50.           Bezemer ID, Verhamme KM, Gini R, Mosseveld M, Rijnbeek PR, Trifirò G, et al. Use of oral contraceptives in three European countries: a population-based multi-database study. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 2016;21(1):81-7.

51.           Berkhout J, Stone JA, Verhamme KM, Danhof M, Post TM. Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women. CPT: pharmacometrics & systems pharmacology. 2016;5(12):656-64.

52.           Osokogu OU, Fregonese F, Ferrajolo C, Verhamme K, de Bie S, t Jong G, et al. Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems. Drug Saf. 2015;38(2):207-17.

53.           Noordam R, Aarts N, Verhamme KM, Sturkenboom MC, Stricker BH, Visser LE. Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study. Eur J Clin Pharmacol. 2015;71(3):369-75.

54.           Engelkes M, Janssens HM, de Ridder MA, de Jongste JC, Sturkenboom MC, Verhamme KM. Time trends in the incidence, prevalence and age at diagnosis of asthma in children. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2015;26(4):367-74.

55.           Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396-407.

56.           de Bie S, Ferrajolo C, Straus SM, Verhamme KM, Bonhoeffer J, Wong IC, et al. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project. PloS one. 2015;10(6):e0130399.

57.           de Bie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifirò G, Schuemie MJ, et al. The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. British journal of clinical pharmacology. 2015;80(2):304-14.

58.           Berkhout J, Stone JA, Verhamme KM, Stricker BH, Sturkenboom MC, Danhof M, et al. Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis. CPT: pharmacometrics & systems pharmacology. 2015;4(9):516-26.

59.           Bardai A, Blom MT, van Noord C, Verhamme KM, Sturkenboom MC, Tan HL. Sudden cardiac death is associated both with epilepsy and with use of antiepileptic medications. Heart (British Cardiac Society). 2015;101(1):17-22.

60.           Verhamme KM, van Blijderveen N, Sturkenboom MC. Tiotropium and the risk of death in COPD. The New England journal of medicine. 2014;370(5):481-2.

61.           Verhamme KM, Sturkenboom MC, Brusselle GG. Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD. Eur Respir J. 2014;43(6):1818-9.

62.           van Blijderveen JC, Straus SM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM. A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands. Int Urol Nephrol. 2014;46(3):583-92.

63.           van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, et al. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. The American journal of medicine. 2014;127(8):763-71.

64.           van Blijderveen JC, Straus SM, de Ridder MA, Stricker BH, Sturkenboom MC, Verhamme KM. Adherence to renal function monitoring guidelines in patients starting antihypertensive therapy with diuretics and RAAS inhibitors: a retrospective cohort study. Drug Saf. 2014;37(5):369-77.

65.           Ferrajolo C, Coloma PM, Verhamme KM, Schuemie MJ, de Bie S, Gini R, et al. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. Drug Saf. 2014;37(2):99-108.

66.           Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG, Sturkenboom MC. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J. 2013;42(3):606-15.

67.           van Blijderveen JC, Verhamme KM, Zietse R, Visser LE, Romio SA, Buhre PN, et al. Overanticoagulation is associated with renal function decline. Journal of nephrology. 2013;26(4):691-8.

68.           Pyxaras SA, Mangiacapra F, Verhamme K, Di Serafino L, De Vroey F, Toth G, et al. Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2013;82(4):604-11.

69.           Ferrajolo C, Verhamme KM, Trifirò G, t Jong GW, Giaquinto C, Picelli G, et al. Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries. Drug Saf. 2013;36(10):1007-16.

70.           Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322-9.

71.           Afzal Z, Engelkes M, Verhamme KM, Janssens HM, Sturkenboom MC, Kors JA, et al. Automatic generation of case-detection algorithms to identify children with asthma from large electronic health record databases. Pharmacoepidemiology and drug safety. 2013;22(8):826-33.

72.           Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2012;17(46).

73.           Verhamme KM, Afonso AS, van Noord C, Haag MD, Koudstaal PJ, Brusselle GG, et al. Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. Pulmonary pharmacology & therapeutics. 2012;25(1):19-26.

74.           Trifirò G, Mokhles MM, Dieleman JP, van Soest EM, Verhamme K, Mazzaglia G, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf. 2012;35(2):159-71.

75.           Mokhles MM, Trifirò G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. Pharmacological research. 2012;65(3):358-64.

76.           de Bie S, Verhamme KM, Straus SM, Stricker BH, Sturkenboom MC. Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection. Drug Saf. 2012;35(4):335-46.

77.           Verhamme K, Sturkenboom M. Study designs in paediatric pharmacoepidemiology. Eur J Clin Pharmacol. 2011;67 Suppl 1:67-74.

78.           van Durme YM, Lahousse L, Verhamme KM, Stolk L, Eijgelsheim M, Loth DW, et al. Mendelian randomization study of interleukin-6 in chronic obstructive pulmonary disease. Respiration; international review of thoracic diseases. 2011;82(6):530-8.

79.           Sen EF, Verhamme KM, Neubert A, Hsia Y, Murray M, Felisi M, et al. Assessment of pediatric asthma drug use in three European countries; a TEDDY study. European journal of pediatrics. 2011;170(1):81-92.

80.           Sen EF, Verhamme KM, Felisi M, t Jong GW, Giaquinto C, Picelli G, et al. Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age. British journal of clinical pharmacology. 2011;71(6):943-50.

81.           Muller O, Mangiacapra F, Ntalianis A, Verhamme KM, Trana C, Hamilos M, et al. Long-term follow-up after fractional flow reserve-guided treatment strategy in patients with an isolated proximal left anterior descending coronary artery stenosis. JACC Cardiovascular interventions. 2011;4(11):1175-82.

82.           Afonso AS, Verhamme KM, Sturkenboom MC, Brusselle GG. COPD in the general population: prevalence, incidence and survival. Respiratory medicine. 2011;105(12):1872-84.

83.           Afonso AS, Verhamme KM, Stricker BH, Sturkenboom MC, Brusselle GG. Inhaled anticholinergic drugs and risk of acute urinary retention. BJU international. 2011;107(8):1265-72.

84.           van Noord C, Dieleman JP, van Herpen G, Verhamme K, Sturkenboom MC. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003-14.

85.           Neubert A, Verhamme K, Murray ML, Picelli G, Hsia Y, Sen FE, et al. The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands. Pharmacological research. 2010;62(3):243-8.

86.           Kaur G, Verhamme KM, Dieleman JP, Vanrolleghem A, van Soest EM, Stricker BH, et al. Association between calcium channel blockers and gingival hyperplasia. Journal of clinical periodontology. 2010;37(7):625-30.

87.           Hsia Y, Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Sen F, et al. Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia. 2010;51(5):789-96.

88.           Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, et al. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. British journal of clinical pharmacology. 2010;70(5):721-8.

89.           Cuisset T, Hamilos M, Delrue M, Frère C, Verhamme K, Bartunek J, et al. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome. Thrombosis and haemostasis. 2010;103(4):774-9.

90.           Van Gysel D, Govaere E, Verhamme KM, Doli E, De Baets F. Messages from the Aalst Allergy Study. World journal of pediatrics : WJP. 2009;5(3):182-90.

91.           Van Gysel D, Govaere E, Verhamme K, Doli E, De Baets F. Exposure to pets and the association with sensitization and allergic disease in Belgian schoolchildren. Allergy. 2009;64(4):663-4.

92.           Van Gysel D, Govaere E, Verhamme K, Doli E, De Baets F. Body mass index in Belgian schoolchildren and its relationship with sensitization and allergic symptoms. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2009;20(3):246-53.

93.           van Durme YM, Verhamme KM, Aarnoudse AJ, Van Pottelberge GR, Hofman A, Witteman JC, et al. C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2009;179(5):375-82.

94.           van Durme Y, Verhamme KMC, Stijnen T, van Rooij FJA, Van Pottelberge GR, Hofman A, et al. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest. 2009;135(2):368-77.

95.           Govaere E, Van Gysel D, Verhamme KM, Doli E, Oranje AP, De Baets F. The prevalence, characteristics of and risk factors for eczema in Belgian schoolchildren. Pediatric dermatology. 2009;26(2):129-38.

96.           Govaere E, Van Gysel D, Verhamme KM, Doli E, De Baets F. The association of allergic symptoms with sensitization to inhalant allergens in childhood. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2009;20(5):448-57.

97.           Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373-88.

98.           van der Hooft CS, Dieleman JP, Siemes C, Aarnoudse AJ, Verhamme KM, Stricker BH, et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiology and drug safety. 2008;17(4):365-71.

99.           Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, et al. Drug use in children: cohort study in three European countries. Bmj. 2008;337:a2245.

100.         Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Nicolosi A, Giaquinto C, et al. Databases for pediatric medicine research in Europe--assessment and critical appraisal. Pharmacoepidemiology and drug safety. 2008;17(12):1155-67.

101.         Madaric J, Mistrik A, Riecansky I, Vulev I, Pacak J, Verhamme K, et al. Left internal mammary artery bypass dysfunction after revascularization of moderately narrowed coronary lesions. Colour-duplex ultrasound versus angiography study. European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology. 2008;9(2):273-7.

102.         Verhamme KM, Sturkenboom MC. Mortality in men admitted to hospital with acute urinary retention. Bmj. 2007;335(7631):1164-5.

103.         Verhamme KM, Mosis G, Dieleman JP, Stricker BH, Sturkenboom MC. [Increased risk of gastrointestinal bleeding or ulcers when using spironolactone: a case-control study]. Nederlands tijdschrift voor geneeskunde. 2007;151(27):1515-21.

104.         Verhamme KM, De Coster W, De Roo L, De Beenhouwer H, Nollet G, Verbeke J, et al. Pathogens in early-onset and late-onset intensive care unit-acquired pneumonia. Infection control and hospital epidemiology. 2007;28(4):389-97.

105.         Vanwynsberghe T, Verhamme K, Raymaekers M, Cartuyvels R, Boel A, De Beenhouwer H. Outbreak of Klebsiella pneumoniae strain harbouring an AmpC (DHA-1) and a blaSHV-11 in a Belgian hospital, August-December 2006. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2007;12(2):E070201.3.

106.         van Soest EM, Sturkenboom MC, Dieleman JP, Verhamme KM, Siersema PD, Kuipers EJ. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007;26(2):265-75.

107.         Van Gysel D, Govaere E, Verhamme K, Doli E, De Baets F. The influence of atopic status and potential risk factors for sensitization on histamine skin reactivity in unselected Belgian children. Pediatric dermatology. 2007;24(4):363-8.

108.         Van Gysel D, Govaere E, Verhamme K, Doli E, De Baets F. The influence of bedroom environment on sensitization and allergic symptoms in schoolchildren. Journal of investigational allergology & clinical immunology. 2007;17(4):227-35.

109.         Trifirò G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiology and drug safety. 2007;16(5):538-44.

110.         Madaric J, Vanderheyden M, Van Laethem C, Verhamme K, Feys A, Goethals M, et al. Early and late effects of cardiac resynchronization therapy on exercise-induced mitral regurgitation: relationship with left ventricular dyssynchrony, remodelling and cardiopulmonary performance. European heart journal. 2007;28(17):2134-41.

111.         Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. European urology. 2007;51(1):207-15; discussion 15-6.

112.         Govaere E, Van Gysel D, Massa G, Verhamme KM, Doli E, De Baets F. The influence of age and gender on sensitization to aero-allergens. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2007;18(8):671-8.

113.         Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. Bmj. 2006;333(7563):330.

114.         Manoharan G, Pijls NH, Lameire N, Verhamme K, Heyndrickx GR, Barbato E, et al. Assessment of renal flow and flow reserve in humans. Journal of the American College of Cardiology. 2006;47(3):620-5.

115.         De Bruyne B, Manoharan G, Pijls NH, Verhamme K, Madaric J, Bartunek J, et al. Assessment of renal artery stenosis severity by pressure gradient measurements. Journal of the American College of Cardiology. 2006;48(9):1851-5.

116.         Verhamme KM, Dieleman JP, Van Wijk MA, van der Lei J, Bosch JL, Stricker BH, et al. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Archives of internal medicine. 2005;165(13):1547-51.

117.         Verhamme KM, Dieleman JP, van Wijk MA, Bosch JL, Stricker BH, Sturkenboom MC. Low incidence of acute urinary retention in the general male population: the triumph project. European urology. 2005;47(4):494-8.

118.         van der Hooft CS, Jong GW, Dieleman JP, Verhamme KM, van der Cammen TJ, Stricker BH, et al. Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria--a population-based cohort study. British journal of clinical pharmacology. 2005;60(2):137-44.

119.         Madaric J, Vulev I, Bartunek J, Mistrik A, Verhamme K, De Bruyne B, et al. Frequency of abdominal aortic aneurysm in patients >60 years of age with coronary artery disease. The American journal of cardiology. 2005;96(9):1214-6.

120.         Madaric J, Bartunek J, Verhamme K, Penicka M, Van Schuerbeeck E, Nellens P, et al. Hyperdynamic myocardial response to beta-adrenergic stimulation in patients with chest pain and normal coronary arteries. Journal of the American College of Cardiology. 2005;46(7):1270-5.

121.         Verhamme KM, Bosch RJ, Sturkenboom MC. Finasteride in benign prostatic hyperplasia. The New England journal of medicine. 2004;350(13):1359-61; author reply -61.

122.         Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. European urology. 2003;44(5):539-45.

123.         Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. European urology. 2002;42(4):323-8.

Abstracts presented at Conferences Proceedings

1.             Russom, M., K. Verhamme, L. Karimi, and H. Ahmed, Nature, Magnitude and Risk Factors of Adverse Drug Reactions in Multidrug Resistant TB Patients in Eritrea. European Respiratory Journal, 2018. 52.

2.             Reyes, C., M. Aragon, P. Rijnbeek, J. Van der Lei, K. Verhamme, and D. Prieto-Alhambra, Validation of Copd Icd10 Diagnostic Codes in the Sidiap Primary Health Care Research Database Using a Combination of Spirometry Measures, Symptoms, Drug Use, and Free Text Review. Value in Health, 2018. 21: p. S368-S368.

3.             Mulder, M., E. Baan, A. Verbon, B. Stricker, and K. Verhamme, Prescribing antimicrobial drugs for urinary tract infections in primary care in the Netherlands. Pharmacoepidemiology and Drug Safety, 2018. 27: p. 365-365.

4.             Karimi, L., L. Lahousse, B.H.C. Stricker, J. Van der Lei, K.M. Verhamme, and G.G. Brusselle, beta 2-adrenergic receptor polymorphisms and risk of COPD. European Respiratory Journal, 2018. 52.

5.             Karimi, L., E.J. Baan, T. Geeraerd, J. Van der Lei, B.H.C. Stricker, G.G. Brusselle, L. Lahousse, and K.M. Verhamme, Real life data on COPD treatment. Pharmacoepidemiology and Drug Safety, 2018. 27: p. 441-442.

6.             Karimi, L., E.J. Baan, T. Geeraerd, J. Van der Lei, B.H.C. Stricker, G.G. Brusselle, L. Lahousse, and K.M. Verhamme, Real-life data on COPD treatment. European Respiratory Journal, 2018. 52.

7.             Baan, E.J., E.L.T. Van den Akker, Y.B. De Rijke, J.C. De Jongste, M. Sturkenboom, K.M. Verhamme, M. Engelkes, and H.M. Janssens, The effect of inhaled corticosteroids on hair cortisol. European Respiratory Journal, 2018. 52.

8.             Baan, E.J., L. Karimi, A. Heeremans, G.G. Brusselle, M. Sturkenboom, H.M. Janssens, L. Lahousse, and K.M. Verhamme, Asthma treatment in real life. European Respiratory Journal, 2018. 52.

9.             Baan, E.J., M. de Ridder, M. Engelkes, E. Svensson, D. Prieto-Alhambra, F. Lapi, C. Giaquinto, G. Picelli, F. Albers, L. Evitt, E. Bradford, M.K. van Dyke, P. Rijnbeek, M. Sturkenboom, H.M. Janssens, and K.M.C. Verhamme, Incidence and risk factors of pediatric asthma exacerbations in a multinational, multidatabase cohort study. European Respiratory Journal, 2018. 52.

10.           Vijverberg, S.J.H., N. Hernandez-Pacheco, N. Farzan, B. Francis, C. Flores, M. Schieck, P. Soares, L. Karimi, R. Tavendale, V. Berce, K. Repnik, K.M.C. Verhamme, U. Potocnik, S. Mukhopadhyay, M. Pirmohamed, C.N. Palmer, S.W. Turner, D.B. Hawcutt, M. Kabesch, M. Pino-Yanes, and A.H. Maitland-van der Zee, Genome-Wide Association Study of Asthma Exacerbations in European Children Treated with Inhaled Corticosteroids. Pharmacoepidemiology and Drug Safety, 2017. 26: p. 25-26.

11.           Vijverberg, S.J.H., N. Hernandez-Pacheco, N. Farzan, B. Francis, C. Flores, M. Schieck, P. Soares, L. Karimi, R. Tavendale, V. Berce, K. Repnik, K. Verhamme, U. PotocNik, S. Mukhopadhyay, M. Pirmohamed, C. Palmer, S. Turner, D. Hawcutt, M. Kabesch, M. Pino-Yanes, and A.H. Maitland-Van der Zee, Genome-wide association study of asthma exacerbations in European children treated with inhaled corticosteroids. European Respiratory Journal, 2017. 50.

12.           Terzikhan, N., L. Lahousse, K. Verhamme, O. Franco, G. Brusselle, and B. Stricker, Increased risk of peripheral arterial disease in individuals with COPD. European Respiratory Journal, 2017. 50.

13.           Osokogu, O.U., A. Pacurariu, M. Mosseveld, P. Rijnbeek, D. Weibel, K. Verhamme, and M. Sturkenboom, Impact of Different Assumptions on Incidence Estimates of Pediatric Diseases Derived from Healthcare Data: A Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety, 2017. 26: p. 104-105.

14.           Osokogu, O., J. Khan, S. Nakato, D. Weibel, M. de Ridder, M. Sturkenboom, and K. Verhamme, Comparing Drug Effectiveness in Children Using Propensity Scores Based on Different Windows of Patient History: A Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety, 2017. 26: p. 421-421.

15.           Farzan, N., S.J. Vijverberg, N. Hernandez-Pacheco, V. Berce, E.G. Burchard, G. Canino, J.C. Celedon, M.M. Cloutier, E. Forno, B. Francis, D.B. Hawcutt, M. Kabesch, L. Karimi, E. Melen, S. Mukhopadhyay, S. Nilsson, C.N. Palmer, M. Pino-Yanes, M. Pirmohamed, U. Potocnik, J.A. Raaijmakers, K. Repnik, M. Schieck, R.L. Smyth, K.G. Tantisira, R. Tavendale, S.M. Tse, S. Turner, K.M. Verhamme, and A.H. Maitland-Van der Zee, 17q21 gene variation increases the risk of exacerbations in asthmatic children treated with inhaled corticosteroids: A meta-analysis in the multi-ethnic pica consortium. Allergy, 2017. 72: p. 269-270.

16.           Farzan, N., S. Vijverberg, N. Hernandez-Pacheco, V. Berce, E.G. Burchard, G. Canino, J.C. Celedon, M.M. Cloutier, E. Forno, B. Francis, D. Hawcutt, M. Kabesch, L. Karimi, E. Melen, S. Mukhopadhyay, S. Nilsson, C. Palmer, M. Pino-Yanes, M. Pirmohamed, U. Potocnik, J. Raaijmakers, K. Repnik, M. Schieck, R. Smyth, K. Tantisira, S. Turner, K. Verhamme, and A.H. Maitland-van Der Zee, 17q21 Gene Variance Increases The Risk Of Exacerbations In Asthmatic Children Treated With Inhaled Corticosteroids: A Meta-Analysis In The Pica Consortium. American Journal of Respiratory and Critical Care Medicine, 2017. 195.

17.           De Smet, V.A., E. Baan, A. Pacurariu, S. Commeyne, M. Sturkenboom, J. De Jongste, H. Janssens, and K.M.C. Verhamme, Safety Signals Concerning Asthma Drugs in Children. Pharmacoepidemiology and Drug Safety, 2017. 26: p. 589-589.

18.           De Smet, V., E. Baan, A.C. Pacurariu, M. Sturkenboom, J.C. De Jongste, H.M. Janssens, and K.M. Verhamme, Safety signals concerning asthma drugs in children. European Respiratory Journal, 2017. 50.

19.           De Roos, E., L. Lahousse, A. Ikram, B. Stricker, G. Brusselle, and K. Verhamme, Prevalence of hypertension among elderly asthmatics: the Rotterdam Study. European Respiratory Journal, 2017. 50.

20.           Baan, E.J., H.M. Janssens, T. Kerckaert, J.C. De Jongste, M. Sturkenboom, and K.M.C. Verhamme, Antibiotic Use in Children with Asthma. Pharmacoepidemiology and Drug Safety, 2017. 26: p. 272-272.

21.           Baan, E.J., H.M. Janssens, T. Kerckaert, J. De Jongste, M.C. Sturkenboom, and K.M. Verhamme, Antibiotic Use In Children With Asthma. American Journal of Respiratory and Critical Care Medicine, 2017. 195.

22.           Baan, E., H. Janssens, T. Kerckaert, J. De Jongste, M. Sturkenboom, and K. Verhamme, Antibiotic use in children with asthma. European Respiratory Journal, 2017. 50.

23.           Verhamme, K.M.C., U. Goditiabois, M. Engelkes, M. Sturkenboom, B.B.C. Stricker, and G.G.O. Brusselle, Use of beta-Blockers and Risk of Asthma Exacerbations. Pharmacoepidemiology and Drug Safety, 2016. 25: p. 110-111.

24.           Verhamme, K.M.C., U. Goditiabois, M. Engelkes, M. Sturkenboom, B. Stricker, and G. Brusselle, Use of beta-blockers and the risk of asthma exacerbations. European Respiratory Journal, 2016. 48.

25.           Verhamme, K.M.C., M. Engelkes, M. de Ridder, E. Svensson, K. Berencsi, D. Prieto-Alhambra, F. Lapi, C. Giaquinto, G. Picelli, N. Boudiaf, F. Albers, S. Cockle, E. Bradford, R. Suruki, H. Muellerova, P. Rijnbeek, and M. Sturkenboom, Multinational, database cohort study to study mortality and risk factors of mortality in patients with asthma. European Respiratory Journal, 2016. 48.

26.           Verhamme, K.M.C., M. De Ridder, L. Pedersen, D. Prieto-Alhambra, F. Lapi, P. Rijnbeek, R.K. Amar, and M. Sturkenboom, Patient characteristics of new initiators of glycopyrronium bromide (GLY) - A multinational, multi-database real-world drug-utilization study. European Respiratory Journal, 2016. 48.

27.           Verhamme, K., M. Engelkes, M. De Ridder, E. Svensson, K. Berencsi, D. Prieto-Alhambra, C. Giaquinto, F. Lapi, G. Picelli, N. Boudiaf, F.C. Albers, S. Cockle, E. Bradford, R. Suruki, P. Rijnbeek, and M. Sturkenboom, Risk Factors Of Severe Asthma Exacerbations: A Real World Study. American Journal of Respiratory and Critical Care Medicine, 2016. 193.

28.           Terzikhan, N., L. Lahousse, D. Bos, L. Wolff, K. Verhamme, O. Franco, B. Stricker, A. van der Lugt, and G. Brusselle, Pulmonary artery to aorta ratio and mortality risk in the general population: The Rotterdam study. European Respiratory Journal, 2016. 48.

29.           Osokogu, O.U., J. Dukanovic, C. Ferrajolo, W.M. Bramer, D. Weibel, G. t' Jong, K. Verhamme, F. Kaguelidou, and M. Sturkenboom, Quality of Pediatric Pharmacoepidemiological Safety Studies Published from 1979 to 2013. Pharmacoepidemiology and Drug Safety, 2016. 25: p. 181-181.

30.           Lahousse, L., P. De Nocker, A. Hofman, B. Stricker, G. Brusselle, and K. Verhamme, LSC Abstract - Potential use of beta-blockers to reduce COPD exacerbations. European Respiratory Journal, 2016. 48.

31.           Kaguelidou, F., S. De Bie, K. Verhamme, M.D. Ridder, G. Picelli, S. Strauss, C. Giaquinto, B. Stricker, J. Bielicki, M. Sharland, and M. Sturkenboom, New quality indicators for paediatric antibiotic prescribing in primary care: a population based cohort study in the United Kingdom, Italy and the Netherlands from 1995 to 2010. Fundamental & Clinical Pharmacology, 2016. 30: p. 19-19.

32.           Farzan, N., S.J. Vijverberg, A.K. Andiappan, N. Blanca-Lopez, K. Bonnelykke, P. Campo, G. Canino, B. Carleton, J.C. Celedon, F.T. Chew, M.M. Cloutier, D. Daley, N. Dijk, L. Duijts, C. Flores, E. Frono, D.B. Hawcutt, M. Kabesch, G.H. Koppelman, V.G. Manolopoulos, E. Melen, S. Mukhopadhyay, S. Nilsson, C.N. Palmer, M. Pino-Yanes, M. Pirmohamed, U. Potocnik, J.A. Raaijmakers, K. Repnik, M. Schieck, R. Smyth, P. Soares, C. Szalai, K.G. Tantisira, S. Turner, M.P. van der Schee, K.M. Verhamme, and A.H. Maitland-van der Zee, Defining uncontrolled childhood asthma in the global PiCA consortium. European Respiratory Journal, 2016. 48.

33.           Farzan, N., S.J. Vijverberg, A. Andiappan, C.J. Palmer, K.G. Tantisira, L. Duijts, M. Pino-Yanes, E. Melen, D. Hawcutt, K.M. Verhamme, C. Flores, D. Daley, S. Mukhopadhyay, F.T. Chew, K. Bonnelykke, V.G. Manolopoulos, M. Kabesch, G.H. Koppelman, U. Potocnik, B. Carleton, S. Turner, J. Raaijmakers, and A.H. Maitland-Van Der Zee, Defining uncontrolled childhood asthma in the global PiCA consortium. Allergy, 2016. 71: p. 53-53.

34.           Terzikhan, N., K.M.C. Verhamme, A. Hofman, B.H. Stricker, G.G. Brusselle, and L. Lahousse, Prevalence and incidence of COPD: The Rotterdam study. European Respiratory Journal, 2015. 46.

35.           Engelkes, M., B.N. Van, K. Verhamme, J.A. Overbeek, J.G. Kuiper, R.M. Herings, M. Sturkenboom, J. de Jongste, and H. Janssens, Prevalence of Switching from Brand to Generic Asthma Medications. Value in Health, 2015. 18(7): p. A505-A506.

36.           Engelkes, M., N.C. van Blijderveen, K.M.C. Verhamme, J.A. Overbeek, J.G. Kuiper, R.C.M. Herings, M. Sturkenboom, J.C. de Jongste, and H.M. Janssens, Prevalence of switching from brand to generic asthma medications in the Netherlands. Pharmacoepidemiology and Drug Safety, 2015. 24: p. 135-136.

37.           Engelkes, M., N. Van Blijderveen, K. Verhamme, J. Overbeek, J. Kuiper, R. Herings, M. Sturkenboom, J. De Jongste, and H. Janssens, Prevalence of switching from brand to generic asthma medications. European Respiratory Journal, 2015. 46.

38.           Engelkes, M., H.M. Janssens, J.C. de Jongste, M. Sturkenboom, and K.M.C. Verhamme, Adherence to Inhaled Corticosteroids in Asthmatic Children in Dutch Primary Care. Pharmacoepidemiology and Drug Safety, 2015. 24: p. 503-503.

39.           Engelkes, M., H. Janssens, J. De Jongste, M. Sturkenboom, and K. Verhamme, Adherence to inhaled corticosteroids in asthmatic children in Dutch primary care. European Respiratory Journal, 2015. 46.

40.           Engelkes, M., M. de Ridder, E. Svensson, K. Berensci, D. Prieto-Alhambra, F. Lapi, C. Giaquinto, G. Picelli, N. Boudiaf, F. Albers, S. Cockle, E. Bradford, R. Suruki, P. Rijnbeek, M. Sturkenboom, and K. Verhamme, LATE-BREAKING ABSTRACT: Multinational, database cohort study to assess all-cause mortality following severe asthma exacerbations. European Respiratory Journal, 2015. 46.

41.           Engelkes, M., M. de Ridder, E. Svensson, K. Berensci, D. Prieto-Alhambra, F. Lapi, C. Giaquinto, G. Picelli, N. Boudiaf, F. Albers, S. Cockle, E. Bradford, R. Suruki, P. Rijnbeek, M. Sturkenboom, and K. Verhamme, LATE-BREAKING ABSTRACT: Multinational, database cohort study to assess severe exacerbation rate in asthma. European Respiratory Journal, 2015. 46.

42.           Ferrajolo, C., O. Osokogu, C. Nan, Y.B. Pernus, D. Weibel, K. Verhamme, M. Gazarian, I.C.K. Wong, H. Nakamura, J. Bonhoeffer, C. Giaquinto, and M. Sturkenboom, Healthcare Databases for Paediatric Studies: A Report from the GRiP Network Global Survey. Pharmacoepidemiology and Drug Safety, 2014. 23: p. 153-153.

43.           Ferrajolo, C., M. Engelkes, K.M.C. Verhamme, G. Trifiro, A. Capuano, and M. Sturkenboom, Association between Use of Asthma Drugs in Children and Hepatotoxicity. Pharmacoepidemiology and Drug Safety, 2014. 23: p. 186-187.

44.           Engelkes, M., H.M. Janssens, J.C. de Jongste, M. Sturkenboom, and K.M.C. Verhamme, Long-Acting beta 2 Agonist Without Concomitant Inhaled Corticosteroids in Children with Asthma in Primary Care. Pharmacoepidemiology and Drug Safety, 2014. 23: p. 152-153.

45.           Engelkes, M., H. Janssens, M. de Ridder, M. Sturkenboom, J. de Jongste, and K. Verhamme, Epidemiology and characteristics of severe asthma exacerbations in children. European Respiratory Journal, 2014. 44.

46.           Engelkes, M., H. Janssens, J. de Jongste, M. Sturkenboom, and K. Verhamme, Long-acting beta 2 agonist without concomitant inhaled corticosteroids in children with asthma in primary care. European Respiratory Journal, 2014. 44.

47.           Verhamme, K., N. van Blijderveen, S. Romio, B. Stricker, G. Brusselle, and M. Sturkenboom, Chronic kidney disease as effect modifier in the association between the use of tiotropium respimat and mortality. European Respiratory Journal, 2013. 42.

48.           van Blijderveen, J.C., S.M. Straus, M.C. Sturkenboom, B.C. Stricker, and K.M. Verhamme, Burden of Chronic Kidney Disease. Pharmacoepidemiology and Drug Safety, 2013. 22: p. 412-412.

49.           van Blijderveen, J.C., S.M. Straus, M.C. Sturkenboom, B.C. Stricker, and K.M. Verhamme, When Follow-Up Time Cannot Be Assigned: Chronic Kidney Disease and It's Diagnosis. Pharmacoepidemiology and Drug Safety, 2013. 22: p. 308-308.

50.           Osokogu, O., F. Fregonese, D. Weibel, K. Verhamme, M. Catapano, S. De Bie, M. Sturkenboom, C. Ferrajolo, P. Coloma, G. t'Jong, M. Schuemie, I. Wong, Y.F. Hsia, M. Gazarian, and H. Nakamura, Creating a Reference Set for Comparing Data Mining Methods and Evaluating Database Performance in Children - The GRiP Project. Pharmacoepidemiology and Drug Safety, 2013. 22: p. 344-344.

51.           Ferrajolo, C., K.M.C. Verhamme, G. Trifiro, G.W. t' Jong, G. Picelli, C. Giaquinto, G. Mazzaglia, C. Cricelli, F. Rossi, A. Capuano, and M. Sturkenboom, Antibiotics and Hepatotoxicity in Pediatric Primary Care: A Case-Control Study Using Electronic Healthcare Databases. Pharmacoepidemiology and Drug Safety, 2013. 22: p. 177-177.

52.           Ferrajolo, C., K.M. Verhamme, G. Trifiro, B. Stricker, G. Picelli, C. Giaquinto, C. Cricelli, F. Rossi, A. Capuano, and M.C. Sturkenbooom, Antibiotics and Liver Injury in Paediatric Primary Care: a Case-Control Study using Healthcare Database Network. Drug Safety, 2013. 36(9): p. 853-853.

53.           Ferrajolo, C., P. Coloma, K.M. Verhamme, M.J. Schuemie, R. Gini, R. Herings, G. Mazzaglia, G. Picelli, C. Giaquinto, L. Scotti, P. Avillach, L. Pedersen, F. Rossi, A. Capuano, J. Van der Lei, G. Trifiro, and M.M. Sturkenboom, Identifying Potentially Drug-Induced Acute Liver Injury in Children Using a Multinational Healthcare Database Network. Drug Safety, 2013. 36(9): p. 881-882.

54.           Engelkes, M., H.M. Janssens, J.C. Jongste, M. Sturkenboom, and K.M.C. Verhamme, Medication Adherence and Severe Asthma Exacerbations: Systematic Review. Pharmacoepidemiology and Drug Safety, 2013. 22: p. 110-111.

55.           Engelkes, M., H.M. Janssens, Z. Afzal, J.C. de Jongste, M. Sturkenboom, and K.M.C. Verhamme, Prescription Patterns and Treatment Adherence of Asthma Controller Therapies in Children in a Dutch Primary Care Database. Pharmacoepidemiology and Drug Safety, 2013. 22: p. 335-336.

56.           Engelkes, M., H. Janssens, J. de Jongste, M. Sturkenboom, and K. Verhamme, Medication adherence and risk of severe exacerbations in asthma- A systematic review. European Respiratory Journal, 2013. 42.

57.           Engelkes, M., H. Janssens, Z. Afzal, J. de Jongste, M. Sturkenboom, and K. Verhamme, Prescription patterns and treatment adherence of asthma controller therapy in children in a Dutch primary care database. European Respiratory Journal, 2013. 42.

58.           de Bie, S., K.M.C. Verhamme, M.G. Garcia, G. Picelli, S. Straus, B. Oliva, M. Felisi, B.H.C. Stricker, F.J. de Abajo, and M. Sturkenboom, Increasing Utilization of Proton Pump Inhibitors in Children: A Cohort Study in Three European Countries. Pharmacoepidemiology and Drug Safety, 2013. 22: p. 333-333.

59.           de Bie, S., S. Straus, K.M.C. Verhamme, C. Ferrajolo, J. Bonhoeffer, I. Wong, and M. Sturkenboom, Pediatric Drug Safety Surveillance in FDA-AERS, a Description of Adverse Events: A GRiP Study. Pharmacoepidemiology and Drug Safety, 2013. 22: p. 381-381.

60.           Bezemer, I.D., K.M.C. Verhamme, R. Gini, M. Mosseveld, P.R. Rijnbeek, M. Sturkenboom, F.J.A. Penning-van Beest, and R.M.C. Herings, User and Treatment Characteristics of Oral Contraceptives in the European Union. Pharmacoepidemiology and Drug Safety, 2013. 22: p. 416-416.

61.           Bezemer, I.D., K.M. Verhamme, R. Gini, M. Mosseveld, P.R. Rijnbeek, M.C. Sturkenboom, F.J.A. Penning-van Beest, and R.M.C. Herings, User and Treatment Characteristics of Oral Contraceptives in the European Union. Value in Health, 2013. 16(7): p. A340-A340.

62.           Verhamme, K.M.C., A.S. Afonso, S. Romio, B.B.C. Stricker, G.G.O. Brusselle, and M. Sturkenboom, Increased Risk of Mortality in COPD Patients Using Tiotropium Respimat vs. Tiotropium Handihaler. Pharmacoepidemiology and Drug Safety, 2012. 21: p. 476-477.

63.           Verhamme, K.M., S. de Bie, T. Beukelman, S.A. Oliveria, T. Lasky, and R. Sobel, Small Patients, Big Challenges - Current Topics in Pediatric Pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2012. 21: p. 339-340.

64.           Verhamme, K., A. Afonso, S. Romio, B. Stricker, G. Brusselle, and M. Sturkenboom, Increased risk of mortality in COPD patients using tiotropium respimat vs. tiotropium Handihaler. European Respiratory Journal, 2012. 40.

65.           van Blijderveen, J.C., K.M. Verhamme, M.C. Sturkenboom, S.A. Romio, S.M. Straus, and B.C. Stricker, Renal Function Impairment by Overanticoagulation? Pharmacoepidemiology and Drug Safety, 2012. 21: p. 112-113.

66.           Ferrajolo, C., K.M.C. Verhamme, G. Trifiro, G.W. t Jong, G. Picelli, C. Giaquinto, G. Mazzaglia, C. Cricelli, F. Rossi, A. Capuano, and M. Sturkenboom, Hepatic Safety of Antibiotics in Paediatric Primary Care: A Case-Control Study Using Electronic Healthcare Databases. Drug Safety, 2012. 35(10): p. 948-949.

67.           Ferrajolo, C., G. Trifiro, P.M. Coloma, K.M.C. Verhamme, M.J. Schuemie, R. Gini, R. Herings, G. Mazzaglia, G. Picelli, C. Giaquinto, L. Scotti, P. Avillach, L. Pedersen, J. van der Lei, and M. Sturkenboom, Pediatric Acute Liver Injury: Signal Detection Using Multiple Healthcare Databases from EU-ADR Network. Pharmacoepidemiology and Drug Safety, 2012. 21: p. 182-183.

68.           Ferrajolo, C., O. Osokogu, S. De Ble, K.M.C. Verhamme, D. Weibel, F. Fregonese, Y. Li, I.C.K. Wong, H. Nakamura, J. Bonhoeffer, C. Giaquinto, and M. Sturkenboom, Population-Based Healthcare Databases for Paediatric Studies: Early Results from the GRiP Network Global Survey. Drug Safety, 2012. 35(10): p. 949-949.

69.           Ferrajolo, C., P.M. Coloma, G. Trifiro, K.M.C. Verhamme, M.J. Schuemie, R. Gini, R. Herings, G. Mazzaglia, G. Picelli, C. Giaquinto, L. Scotti, P. Avillach, L. Pedersen, J. Van der Lei, and M. Sturkenboom, Paediatric Acute Liver Injury: Signal Detection Using Multiple Healthcare Databases from the EU-ADR Network. Drug Safety, 2012. 35(10): p. 908-909.

70.           Engelkes, M., Z. Afzal, H.M. Janssens, J.A. Kors, M.J. Schuemie, K.M.C. Verhamme, and M. Sturkenboom, Automated Identification of Asthma Patients within an Electronical Medical Record Database Using Machine Learning. Pharmacoepidemiology and Drug Safety, 2012. 21: p. 12-12.

71.           Engelkes, M., Z. Afzal, H. Janssens, J. Kors, M. Schuemie, K. Verhamme, and M. Sturkenboom, Automated identification of asthma patients within an electronical medical record database using machine learning. European Respiratory Journal, 2012. 40.

72.           de Bie, S., K. Verhamme, G. Picelli, S. Straus, C. Giaquinto, B. Stricker, M. Sharland, and M. Sturkenboom, Paediatric Oseltamivir Prescriptions in Primary Care in United Kingdom, Italy and Netherlands during the 2009 A/H1N1 Pandemic. Pharmacoepidemiology and Drug Safety, 2012. 21: p. 132-132.

73.           De Bie, S., Y. Li, C. Ferrajolo, K.M.C. Verhamme, J. Bonhoeffer, I.C.K. Wong, and M. Sturkenboom, Adverse Drug Reactions Reported for Children: What are the Differences Between the FDA AERS and the WHO-UMC VigiBase? Drug Safety, 2012. 35(10): p. 942-943.

74.           De Bie, S., P.M. Coloma, C. Ferrajolo, K.M.C. Verhamme, G. Trifiro, M.J. Schuemie, S. Straus, R. Gini, R.M.C. Herings, G. Mazzaglia, G. Picelli, A. Ghirardi, L. Pedersen, B.H.C. Stricker, J. Van der Lei, and M. Sturkenboom, What Can Electronic Healthcare Record Databases do for Paediatric Drug Safety Surveillance? Drug Safety, 2012. 35(10): p. 902-903.

75.           de Bie, S., P. Coloma, C. Ferrajolo, G. Trifiro, K. Verhamme, M. Schuemie, S. Straus, R. Gini, R. Herings, G. Mazzaglia, G. Picelli, L. Scotti, L. Pedersen, B. Stricker, J. van der Lei, and M. Sturkenboom, The Power of Electronic Healthcare Databases for Active Drug Safety Surveillance in Children and Adolescents: An EU-ADR Study. Pharmacoepidemiology and Drug Safety, 2012. 21: p. 329-330.

76.           Lahousse, L., Y. van Durme, K.M.C. Verhamme, L. Stolk, M. Eijgelsheim, D. Loth, A.G. Uitterlinden, M. Breteler, G.F. Joos, A. Hofman, B.H.C. Stricker, and G.G. Brusselle, Interleukin 6 (IL6) Plasma Levels, Common Variation In The IL6 Gene And The Risk Of Chronic Obstructive Pulmonary Disease: A Prospective Population-Based Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2011. 183.

77.           Ferrajolo, C., K.M.C. Verhamme, A. Capuano, G. Trifiro, A. Oteri, G. Picelli, G. Mazzaglia, C. Cricelli, F. Rossi, and M. Sturkenboom, Risk of Liver Injury in Paediatric Population: Data Mining on Electronic Healthcare Databases in Europe. Basic & Clinical Pharmacology & Toxicology, 2011. 109: p. 139-139.

78.           Ferrajolo, C., K.M.C. Verhamme, A. Capuano, G. Trifiro, A. Oteri, G. Picelli, G. Mazzaglia, C. Cricelli, F. Rossi, and M. Sturkenboom, Incidence Rate of Liver Injury in Pediatric Population: Data Mining on Electronic Healthcare Databases in Europe. Pharmacoepidemiology and Drug Safety, 2011. 20: p. S139-S140.

79.           de Bie, S., K.M.C. Verhamme, S. Straus, B.H.C. Stricker, and M. Sturkenboom, Effect of Vaccine-Related Reports on Pediatric Safety Signal Detection. Pharmacoepidemiology and Drug Safety, 2011. 20: p. S241-S242.

80.           de Bie, S., K.M.C. Verhamme, M.G. Garcia, G. Picelli, S. Straus, B. Oliva, B.H.C. Stricker, A. Ceci, F.J. de Abajo, and M. Sturkenboom, Utilization of Gastro-Intestinal Drugs in Children: Cohort Study in Three European Countries. Pharmacoepidemiology and Drug Safety, 2011. 20: p. S319-S319.

81.           de Bie, S., K.M.C. Verhamme, M.G. Garcia, G. Picelli, S. Straus, B. Oliva, B.H.C. Stricker, A. Ceci, F.J. de Abajo, and M. Sturkenboom, Time Series Analysis of the Effect of Safety Warnings on Prokinetic Drug Prescriptions in Children. Pharmacoepidemiology and Drug Safety, 2011. 20: p. S205-S206.

82.           Afonso, A., K.M.C. Verhamme, G.G.O. Brusselle, and M. Sturkenboom, beta-Blockers and Risk of COPD Exacerbation Requiring Hospitalisation in Patients with COPD. Pharmacoepidemiology and Drug Safety, 2011. 20: p. S65-S66.

83.           Haag, M., K. Verhamme, A. Afonso, C. Van Noord, P. Koudstaal, and M. Sturkenboom, Tiotropium Use and the Risk of Cerebrovascular Events. Pharmacoepidemiology and Drug Safety, 2010. 19: p. S10-S10.

84.           de Bie, S., K.M.C. Verhamme, S. Straus, G.W. t' Jong, B.H.C. Stricker, and M. Sturkenboom, Spontaneous Reports as a Source for Risk Assessment of Long Term Drug Use in Children. Pharmacoepidemiology and Drug Safety, 2010. 19: p. S321-S322.

85.           de Bie, S., K.M.C. Verhamme, S. Straus, G.W. t Jong, B.H.C. Stricker, and M. Sturkenboom, Spontaneous Reports as a Source for Risk Assessment of Long Term Drug Use in Children. Drug Safety, 2010. 33(10): p. 909-909.

86.           de Bie, S., K.M.C. Verhamme, S. Straus, G.W. t Jong, B.H.C. Stricker, and M. Sturkenboom, Applying Data-Mining Techniques to Paediatric Data within the WHO-UMC Database; the Impact of Vaccines. Pharmacoepidemiology and Drug Safety, 2010. 19: p. S86-S87.

87.           de Bie, S., K.M.C. Verhamme, S. Straus, G.W. t Jong, B.H.C. Stricker, and M. Sturkenboom, Detection of Late Effects of Drugs Children Using a Spontaneous Report ADR Database. Pharmacoepidemiology and Drug Safety, 2010. 19: p. S320-S321.

88.           de Bie, S., K.M.C. Verhamme, S. Straus, G.W. t Jong, B.C.H. Stricker, and M. Sturkenboom, Characteristics of Paediatric Individual Case Safety Reports within the WHO-UMC Database. Pharmacoepidemiology and Drug Safety, 2010. 19: p. S318-S318.

89.           de Bie, S., K.M.C. Verhamme, S. Straus, G.W. Jong, B.H.C. Stricker, and M. Sturkenboom, Applying Data-Mining Techniques to Paediatric Data within the WHO-UMC Database; the Impact of Vaccines. Drug Safety, 2010. 33(10): p. 908-908.

90.           Afonso, A., K.M.C. Verhamme, C. van Noord, M. Haag, G.G.O. Brusselle, and M. Sturkenboom, Tiotropium and Severe COPD Exacerbations-Comparisons with Long-Acting beta 2-Mimetics. Pharmacoepidemiology and Drug Safety, 2010. 19: p. S191-S191.

91.           van Noord, C., J.P. Dieleman, K. Verhamme, and M. Sturkenboom, Ventricular Arrhythmia and Sudden Unexpected Death and Domperidone. Pharmacoepidemiology and Drug Safety, 2009. 18: p. S155-S155.

92.           van Durme, Y., K.M.C. Verhamme, G.R. Van Pottelberge, J.C.M. Witteman, A. Aarnoudse, G.F. Joos, A.A. Hofman, G.G. Brusselle, and B.H.C. Stricker, C-Reactive Protein Is a Marker, but Not an Independent Risk Factor To Develop COPD: A Population-Based Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2009. 179.

93.           Ferrajolo, C., K. Verhamme, M. Schuemie, A. Capuano, F. Rossi, B. Stricker, and M. Sturkenboom, Drug-Induced Hepatic Injury in Children: Analysis of Spontaneous Adverse Event Reports of WHO Database. Pharmacoepidemiology and Drug Safety, 2009. 18: p. S168-S168.

94.           Ferrajolo, C., A. Capuano, K.M.C. Verhamme, M. Schuemie, F. Rossi, B.H.C. Stricker, and M. Sturkenboom, Analysis of Individual Case Reports in the WHO Database of Suspected Drug-Induced Hepatic Injury in Children. Drug Safety, 2009. 32(10): p. 946-947.

95.           de Luise, C., G. Trifiro, R. Herings, J. Dieleman, E. van Soest, K. Verhamme, G. Mazzaglia, and M. Sturkenboom, Combining Data from Healthcare Databases in Europe: A Study of Dopamine Agonists. Pharmacoepidemiology and Drug Safety, 2009. 18: p. S184-S184.

96.           de Bie, S., K.M.C. Verhamme, S. Straus, G. Picell, A. Ceci, and M. Sturkenboom, Prokinetic Drugs in Children: Drug Utilization and Safety. Drug Safety, 2009. 32(10): p. 951-951.

97.           de Bie, S., K.M.C. Verhamme, S. Straus, G. Piceli, A. Ceci, and M. Sturkenboom, Prokinetic Drugs in Children; Drug Utilization and Safety. Pharmacoepidemiology and Drug Safety, 2009. 18: p. S155-S156.

98.           Cuisset, T., M. Hamilos, L. Delrue, C. Frere, K. Verhamme, J. Bartunek, J.L. Bonnet, M. Eijgelsheim, M.C. Alessi, and E. Barbato, Adrenergic receptor polymorphisms modulate platelet reactivity after treatment with clopidogrel in acute coronary syndrome. European Heart Journal, 2009. 30: p. 885-885.

99.           Bardai, A., C. van Noord, M.T. Blom, E.M. van Soest, K.M. Verhamme, M.C. Sturkenboom, and H.L. Tan, Anti-Epileptic Drugs Are Associated With Sudden Death. Circulation, 2009. 120(18): p. S417-S417.

100.         Verhamme, K.M.C., M.C. De Smet, and P. Jordens, Use of Fluoroquinolones and the risk of methicillin resistant staphylococcus aurcus (MRSA). Pharmacoepidemiology and Drug Safety, 2008. 17: p. S208-S209.

101.         van Soest, E.M., M. Sturkenboom, J.D. Dieleman, K.C. Verhamme, P.D. Siersema, and E.J. Kuipers, Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal complications. European Journal of Gastroenterology & Hepatology, 2008. 20(7): p. A30-A30.

102.         Sen, E.F., K. Verhamme, G. Picelli, C. Giaquinto, L. Cantarutti, and M. Sturkenboom, Use of cough and cold medications in children in the Netherlands and Italy. Pharmacoepidemiology and Drug Safety, 2008. 17: p. S59-S59.

103.         Kaur, G., K.M.C. Verhamme, J.P. Dieleman, A. Vanrolleghem, E.M. van Soest, B.H.C. Stricker, and M. Sturkenboom, Association between calcium channel blockers and gingival hyperplasia. Pharmacoepidemiology and Drug Safety, 2008. 17: p. S125-S125.

104.         Afonso, A.S.M., K.M.C. Verhamme, B.C. Stricker, G.G.O. Brusselle, and M. Sturkenboom, Inhaled anticholinergic drugs and risk of acute urinary retention. Pharmacoepidemiology and Drug Safety, 2008. 17: p. S24-S24.

105.         Verhamme, K.M.C., G. Picelli, C. Giaquinto, A. Nicolosi, M.L. Murray, A. Neubert, I. Wong, A. Ceci, and M. Sturkenboom, Cardiovascular drug use in children - The teddy project. Pharmacoepidemiology and Drug Safety, 2007. 16: p. S226-S227.

106.         Verhamme, K.M.C., P.M. Elferink-Stinkens, M.L. Murray, A. Neubert, A. Nicolosi, I. Wong, A. Ceci, B.H.C. Stricker, and M. Sturkenboom, Adverse drug reaction reporting in children - The Teddy Project. Pharmacoepidemiology and Drug Safety, 2007. 16: p. S217-S217.

107.         Van Soest, E.M., M.C. Sturkenboom, J.P. Dieleman, K.M. Verhamme, P.D. Siersema, and E.J. Kurpers, Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal complications. Gastroenterology, 2007. 132(4): p. A85-A85.

108.         van Soest, E.M., M. Sturkenboom, J.P. Dieleman, K.M.C. Verhamme, P.D. Siersema, and E.J. Kuipers, Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal complications. Pharmacoepidemiology and Drug Safety, 2007. 16: p. S46-S46.

109.         Van Soest, E., M.C. Sturkenboom, J.P. Dieleman, K. Verhamme, P.D. Siersema, and E. Kuipers, Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal complications. Value in Health, 2007. 10(3): p. A7-A7.

110.         Sturkenboom, M.C., K.M. Verhamme, M.L. Murray, A. Neubert, G. Picelli, C. Giaquinto, A. Nicolosi, I. Wong, and A. Ceci, General drug utilization in children - A multinational database study in The TEDDY project. Pharmacoepidemiology and Drug Safety, 2007. 16: p. S217-S218.

111.         Sturkenboom, M., K. Verhamme, M. Murray, A. Neubert, G. Picelli, C. Giaquinto, A. Nicolosi, I. Wong, and A. Ceci, Respiratory drug use in children: A multinational database study in the TEDDY project. Pharmacoepidemiology and Drug Safety, 2007. 16: p. S169-S169.

112.         Neubert, A., M.L. Murray, M. Sturkenboom, K.M.C. Verhamme, G. Picelli, A. Nicolosi, C. Giaquinto, A. Ceci, and I.C.K. Wong, Drug utilisation of analgesics and anti-inflammatory drugs in children: A multinational database study within the TEDDY project. Pharmacoepidemiology and Drug Safety, 2007. 16: p. S178-S178.

113.         Neubert, A., M.L. Murray, M. Sturken-Boom, K.M.C. Verhamme, A. Nicolosi, C. Giaquinto, A. Ceci, and I.C.K. Wong, Population-based databases for paediatric medicine research in Europe: A TEDDY appraisal. Pharmacoepidemiology and Drug Safety, 2007. 16: p. S218-S218.

114.         Murray, M.L., A.C. Neubert, G. Picelli, M. Sturkenboom, K.M.C. Verhamme, A. Ceci, C. Giaquinto, A. Nicolosi, and I.C.K. Wong, Drug utilisation of neuropsychiatric drugs in children: A multinational study within the TEDDY project. Pharmacoepidemiology and Drug Safety, 2007. 16: p. S161-S162.

115.         Verhamme, K.M.C., G. Mosis, J.P. Dieleman, J. van der Lei, B.H.C. Stricker, and M. Sturkenboom, NSAIDs and the risk of upper gastro-intestinal events: A nested case-control study. Pharmacoepidemiology and Drug Safety, 2006. 15: p. S267-S267.

116.         Verhamme, K.M.C., J.P. Dieleman, M. Van Wijk, J. van der Lei, R. Bosch, B.H.C. Stricker, and M. Sturkenboom, Anti-psychotic drugs and the risk of acute urinary retention. Pharmacoepidemiology and Drug Safety, 2006. 15: p. S35-S36.

117.         van der Hooft, C.S., J.P. Dieleman, C. Siemes, A.J. Aarnoudse, K.M.C. Verhamme, B.H.C. Stricker, and M. Sturkenboom, ADR-Related hospitalisations: A population-based cohort study. Pharmacoepidemiology and Drug Safety, 2006. 15: p. S99-S99.

118.         Trifiro, G., K.M.C. Verhamme, G. Ziere, A.P. Caputi, B.H.C. Stricker, and M. Sturkenboom, All-cause mortality associated with atypical and Typical antipsychotics in demented outpatients: A population-based study. Pharmacoepidemiology and Drug Safety, 2006. 15: p. S221-S222.

119.         Verhamme, K., J. Dieleman, M. van Wijk, J. van der Lei, R. Bosch, B. Stricker, and M. Sturkenboom, Acute urinary retention: Incidence in the general male population and in men with lower urinary tract symptoms/benign prostatic hyperplasia - The triumph project. Journal of Urology, 2004. 171(4): p. 407-407.

120.         Verhamme, K.M., J. Dieleman, G. Bleumink, J. Van der Lei, and M.C. Sturkenboom, Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - Latest analyses from the triumph project. Journal of Urology, 2002. 167(4): p. 273-273.